Preliminary analysis of combined romosozumab and denosumab versus teriparatide and denosumab on bone mineral density
10.1016/j.afos.2025.11.002
- Author:
Ming-Hung CHIANG
1
;
Tian-Sin FAN
;
Chia-Che LEE
;
Tzu-Hao TSENG
;
Hung-Kuan YEN
;
Chih-Chien HUNG
;
Yi-Chien LU
;
Ning-Huei SIE
;
Chen-Yu WANG
;
Shau-Huai FU
Author Information
1. Department of Orthopedic Surgery, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu City, Taiwan
- Publication Type:Original article
- From:Osteoporosis and Sarcopenia
2025;11(4):137-144
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:The effectiveness of combining romosozumab (ROMO) with denosumab (Dmab) remains uncertain.We compare the six-month effects of Dmab plus monthly ROMO versus Dmab plus daily teriparatide (TPTD) on bone mineral density (BMD) in treatment-naïve postmenopausal women with osteoporosis.
Methods:This retrospective cohort study analyzed 26 treatment-naïve postmenopausal women with primary osteoporosis. Participants received either a monthly regimen of ROMO and Dmab (N = 14) or a daily regimen of TPTD plus Dmab (N = 12). BMD at the lumbar spine, total hip, and femoral neck was measured at baseline, 3 months, and 6 months by dual-energy X-ray absorptiometry. Serum levels of C-terminal telopeptide (CTX) and procollagen type I N-terminal propeptide (P1NP) were assessed at the same intervals.
Results:Both regimens significantly improved lumbar spine BMD at 6 months (ROMO + Dmab: +9.75%; TPTD +Dmab: +7.42%). Improvements in total hip and femoral neck BMD were modest and similar between groups (~2%). Serum CTX and P1NP were significantly suppressed in both groups at 3 months, but P1NP suppression waned in the TPTD + Dmab group by 6 months. No statistically significant differences in BMD or marker changes were detected between the two regimens.
Conclusions:Both combination therapies effectively improve lumbar spine BMD over 6 months. The ROMO +Dmab regimen yielded numerically greater increases with fewer injections.
